FDA budget mark-up
This article was originally published in The Gray Sheet
Agency's fiscal year 1999 budget will be marked up by the Senate Appropriations/Agriculture Subcommittee June 9 and by the House Appropriations/Agriculture Subcommitee on June 10. FDA's proposed budget, which calls for flat funding compared to FY 1998 for the Center for Devices and Radiological Health, was reviewed by the House Subcommittee Feb. 25 ("The Gray Sheet" March 2, p. 10) and the Senate March 31 ("The Gray Sheet" April 6, p. 5)...
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.
Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.